SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001694665-23-000034
Filing Date
2023-05-01
Accepted
2023-05-01 07:11:55
Documents
13
Period of Report
2023-04-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K evlo-20230425.htm   iXBRL 8-K 37632
5 evlo-20230425_g1.jpg GRAPHIC 7885
  Complete submission text file 0001694665-23-000034.txt   200624

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evlo-20230425.xsd EX-101.SCH 1903
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evlo-20230425_lab.xml EX-101.LAB 24831
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evlo-20230425_pre.xml EX-101.PRE 13047
7 EXTRACTED XBRL INSTANCE DOCUMENT evlo-20230425_htm.xml XML 11276
Mailing Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 23869955
SIC: 2834 Pharmaceutical Preparations